抄録
Objective: To evaluate the risk of adverse events in patients with rheumatoid arthritis (RA) treated with biological agents (BAs) undergoing lower limb arthroplasty.
Methods: This study included 94 patients with RA who underwent lower limb arthroplasty. Thirty-seven patients were treated with BAs including infliximab (6 patients), etanercept (18 patients), adalimumab (4 patients), tocilizumab (7 patients), abatacept (2 patients), and 57 patients were treated with conventional disease-modifying antirheumatic drugs. We examined the incidence of perioperative adverse events which included surgical site infections (SSIs), delayed wound healing, and RA flare-ups in both the BA- and Non-BA groups. The statistical differences between each group were examined using Fisher's exact test.
Results: Two cases of SSIs were observed in both groups, but there was no statistically significant difference [P = 0.645, OR 1.57 (0.21-11.68)]. One case of delayed wound healing was observed in both groups [P = 1.00, OR 1.56 (0.09-25.68)]. Two cases of RA flare-up were observed in the BA group, but none were observed in the non-BA group [P = 0.152, OR 8.09 (0.38-173.7)].
Conclusion: In this small study, the risk of perioperative adverse events in patients with RA treated with BAs undergoing lower limb arthroplasty was not increased.
